We should be in the calm before the storm as I do not see a company releasing news today. If you were going to announce something to get eyeballs before the conference then you more likely PRed earlier in the week. Releasing something Friday afternoon (outside of something bad to bury the news) does not […]
January 6th Biotech Update
The sector is not having a good start to the year. I saw someone post a chart that compared the performance of the XBI pre-JPM to how it perform during and after JPM. It was really not a strong relationship but in the years where the XBI was red pre-JPM it tended to do poorly […]
January 3rd Biotech Update
2021 is finally over and 2022 enters with hopes of a better year but we all are probably scarred from the year that was 2021. JPM is coming and that brings with it hopes of M&A, positive guidance, and perhaps positive data. Last year it was not great and that ended up being a signal […]
November 4th Biotech Update
The sector has certainly strung a couple of good days together and it is probably in overbought territory as we approach the upper end of this long term range. The top of the range has been around the $137-$142 level and that seems like a pretty large ran for a top. Ideally we would want […]
October 13th Biotech Update
Well, this week is not a disaster and that is positive. We have not built any momentum to the upside but we also do not seem on the verge of breaking down. We are inching closer to a seasonally positive period for the sector and so treading water and forming a base is not bad. […]
September 24th Biotech Update
It really feels like the sector wants to continue the trend higher but the broader market is not going to let it. I think if the broader market sentiment were neutral, then the sector would be moving higher. I do not think the sector has a chance to move higher in the midst of a […]
June 15th Biotech Update
It looked like we could have gotten some momentum but it was not quite able to continue. It was not stock specific but pretty broad based. It is not as if it was a particularly bad day but that momentum that was building that I thought could get us to the $140-1 level on the […]
May 19th Biotech Update
We do not have a ton of news but it has picked up a little this week, which is nice. It is also nice that the news has generally been positive (although not universally so). It is nice to see that the positive news is being treated as such (having positive effects on stock prices) […]
May 6th Biotech Update
Well, yesterday starting really good with PFE finally getting some love and the sector on decent footing but it certainly did not end well. We are now at the recent lows with odds likely favoring breaking the lows and triggering another leg lower. In some ways this is fundamentally and sentiment driven. As I noted […]
Q&A With Sarepta’s Management
It was very tight to get all my questions answered in 30 minutes, but I tried to get as much clarity as I could, let’s get straight to the questions and answers. Q: Why did you decide to expand the 103 study from 11 to 20 patients? A: To adjust the 4-5 & 6-7 years […]
March 19th Biotech (and Energy) Update
Yesterday clearly did not instill a ton of confidence. That being said we did not break any lows so the path of setting a higher low and establishing a new move higher is still possible. The difference is that we are now closer to taking out the lows, which is not a comfortable position (especially […]
March 8th Biotech Update
I am not sure if the sector is trading on fundamentals anymore. I do not mean that it is over- or under- valued but that the trading has been so extreme that I am not sure news matters. Of course, as we attempt to rather this week starts with no M&A and a negative trial […]
January 13th Biotech Update
So I think JPM is a complete failure in terms of news. It is obviously a dud in terms of M&A. I do not remember the last time we had a JPM with zero mergers. There have been some with minor deals but it has been awhile since there have not been any. This actually […]
January 8th Biotech Update
So the sector was doing well yesterday in the lead up to JPM and perhaps we get some early news today but the news yesterday was certainly not a good start and that might end up weighing on the sector (at least in the morning). Hopefully this is not a signal as to the type […]
November 9th Biotech Update
We do not have merger Monday, so I suspect the market will be disappointed. I joke of course as this is going to be a massive relief rally on the news of the PFE vaccine. While there will certainly be a rally that raises almost everyone, there will likely be rotations out of COVID treatment […]
SRPT – The Street Will Get It – Study-103 Is the Fast Path to Full Approval
Last week, Sarepta Therapeutics ( SRPT) on the 3Q earnings call provided key updates on SRP-9001 gene therapy in Duchenne Muscular Dystrophy (DMD). Where they already met the FDA and resolved the FDA’s requests with regard to the potency assays for the commercial material to be used in the next studies, and they came with […]
October 26th Biotech Update
A mixed start to the week with the broader market and sector lower on the open. Nothing dramatic on either and nothing really meaningful in news flow, so a sort of drifting would not be unexpected. I think it is safe to say that we are in the calm before the storm with earnings really […]
October 1st Biotech Update
The sector has been a grind this week in that it appears unable to move higher but also is not breaking down at all. Every rally appears to be sold or unable to get any real traction (the open today is a perfect example in that it looks like we could have a good day […]
September 28th Biotech Update
While there is nothing major happening in the sector, the broader market appears to be recovering and the sector is probably going to be along for the ride. If we can get enough strength this week to push the XBI above the recent highs (around $116.30) then we can start to take more serious the […]
SRPT to Release 2-Years DMD and LGMD-2E GT Data at WMS-2020
It was a surprising and unexpected decision by Sarepta to release the long term data from the first clinical trial of DMD Gene-Therapy, a 2-years data to be presented at the World Muscle Society WMS25 Virtual Congress, despite the previous statements saying, we do not want to release data from an open label study while […]
